Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRR gene-mutated castration-resistant prostate cancer outcomes (HRRCAP)
jRCT1050230026Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Countries
- 1
01
Overview
Open-label trial in prostate cancer (PCa), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Overall survival by HRR-related mutant gene and treatment status and Association of HRR gene alterations with PFS and OS under targeted treatments. Started Nov 2022; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT1050230026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050230026.